References

• 2021Trial of Psilocybin versus Escitalopram for Depression1,404 cited
• 2020Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder1,325 cited
• 2015Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study1,173 cited
• 2021MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study1,041 cited
• 2011Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness893 cited
• 2020Psychedelics and Psychedelic-Assisted Psychotherapy649 cited
• 2020A non-hallucinogenic psychedelic analogue with therapeutic potential468 cited
• 2018Predicting Responses to Psychedelics: A Prospective Study416 cited
• 2014Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects411 cited
• 2018The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act353 cited
• 2021Blinding and expectancy confounds in psychedelic randomized controlled trials319 cited
• 2015Psychedelics not linked to mental health problems or suicidal behavior: A population study302 cited
• 2020Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study284 cited
• 2019Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT